We performed a prospective study to correlate échocardiographie and electrocardiographic left ventricular(LV) hypertrophy with new cardiac events and atherothrombotic brain infarction (ABI) in 360 elderly patients with hypertension or coronary artery disease. The mean follow-up was 37 ± 7 months (range 20-47). Echocardiographie LV hypertrophy was diagnosed if LV mass exceeded 134 g/m2 in men and 110 g/m2 in women. Electrocardiographic LV hypertrophy was diagnosed if the point score of Romhilt and Estes was > 5. New cardiac events occurred in 108 of 182 patients (59%) with échocardiographie LV hypertrophy and in 52 of 178 patients (29%)without échocardiographie LV hypertrophy (p < 0.001). New cardiac events occurred in 25 of 42 patients (60%)with electrocardiographic LV hypertrophy and in 135 of 318 patients (42%) without electrocardiographic LV hypertrophy(p < 0.05). Sensitivity for predicting new cardiac events was 68% for échocardiographie LV hypertrophy and 16% for electrocardiographic LV hypertrophy. New ABI occurred in 60 of 182 patients (33%) with échocardiographie LV hypertrophy and in 21 of 178 patients (12%) without échocardiographie LV hypertrophy (p < 0.001). New ABI occurred in 15 of 42 patients (36%) with electrocardiographic LV hypertrophy and in 66 of 318 patients(21%) without electrocardiographic LV hypertrophy (p < 0.05). Sensitivity for predicting new ABI was 74% foréchocardiographie LV hypertrophy and 19% for electrocardiographic LV hypertrophy. Echocardiographie LV hypertrophy was more sensitive than electrocardiographic LV hypertrophy in predicting new cardiac events (4.3 times)and new ABI (4.0 times) in elderly patients with hypertension or coronary artery disease.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.